期刊
GENE THERAPY
卷 20, 期 1, 页码 7-15出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/gt.2011.205
关键词
oncolytic; measles; melanoma; immunotherapy; HMGB1; interferon
类别
资金
- Medical Research Council (UK)
- Cancer Research UK
- MRC [G0900324] Funding Source: UKRI
- Cancer Research UK [13244] Funding Source: researchfish
- Medical Research Council [G0900324] Funding Source: researchfish
- National Institute for Health Research [ACF-2006-02-006] Funding Source: researchfish
Oncolytic viruses (OV) are promising treatments for cancer, with several currently undergoing testing in randomised clinical trials. Measles virus (MV) has not yet been tested in models of human melanoma. This study demonstrates the efficacy of MV against human melanoma. It is increasingly recognised that an essential component of therapy with OV is the recruitment of host antitumour immune responses, both innate and adaptive. MV-mediated melanoma cell death is an inflammatory process, causing the release of inflammatory cytokines including type-1 interferons and the potent danger signal HMGB1. Here, using human in vitro models, we demonstrate that MV enhances innate antitumour activity, and that MV-mediated melanoma cell death is capable of stimulating a melanoma-specific adaptive immune response. Gene Therapy (2013) 20, 7-15; doi:10.1038/gt.2011.205; published online 15 December 2011
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据